The Charlotte Observer and The News & Observer of Raleigh investigated cancer drug prices at large non-profit hospitals in North Carolina. They found high mark-ups on cancer drug prices. Independent oncology practices provide the same drugs at a significantly reduced price. However, as financially pressured oncology practices merge with hospitals, this low-cost option is diminished.
Hospitals say their higher cancer drug prices are due to several factors, including the need to shift costs to make up for losses elsewhere, according to the report. In addition, hospitals tend to treat sicker patients and more noninsured patients than independent oncology practices, according to the report.
The extent of the markups may negatively affect patient care, causing some patients to delay or forgo needed treatment, according to the report.
More Articles on Hospital Oncology:
MD Anderson Cancer Center to Invest up to $3B in New Cancer Program
Lowell General Hospital, Saints Medical Consolidating Cancer Centers as Part of Merger
ProMedica Fostoria Community Hospital Completes Cancer Center
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
